What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the SOLO-1 trial indicates that olaparib improves progression-free survival compared to placebo, with a hazard ratio of 0.55. However, overall survival data remains immature with only 38.1% maturity, leading to uncertainty in the long-term benefits. While there is moderate benefit shown, the lack of definitive overall survival data prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The most likely cost-effectiveness estimate for olaparib falls within the acceptable range for Healthcare resources, suggesting it is a cost-effective option. The committee noted that the ICER is towards the higher end of the acceptable range, indicating a clear economic advantage.
Is there quality-of-life evidence payers weigh? — Quality of life
The patient expert testimony highlighted that olaparib provides reassurance and potentially improves quality of life by addressing the fear of cancer recurrence. However, specific validated HRQoL data was not detailed in the document, which limits the strength of this evidence.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Olaparib has a very good safety profile with mostly mild to moderate adverse events reported. Serious adverse events are rare, indicating a favorable tolerability compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The only comparator used was routine surveillance, which aligns with the final scope. However, the absence of other established treatments like niraparib and olaparib with bevacizumab limits the robustness of the comparison.
Is the population defined the way payers need it? — Patient Population and Subgroups
The SOLO-1 trial included a representative population of adults with advanced BRCA mutation-positive cancer. However, concerns were raised about the age differences between trial participants and real-world populations, which could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Olaparib can be integrated into existing care pathways with minor adjustments, as it is already used in conjunction with first-line platinum-based chemotherapy. This indicates a manageable transition for healthcare providers.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model suggests that olaparib has a manageable budget impact, with the potential for net savings due to its effectiveness in prolonging progression-free survival.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily based on the robust SOLO-1 Phase 3 trial, although concerns about data maturity and generalizability were noted. Overall, the evidence is strong but has some limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the generalizability of the SOLO-1 trial results, the committee felt that the long follow-up period and the context of unmet need mitigated these concerns.
